Literature DB >> 21861603

Mitogen/extracellular signal-regulated kinase kinase-5 promoter region polymorphisms affect the risk of sporadic colorectal cancer in a southern Chinese population.

Dechang Diao1, Lei Wang, Jun-Xiao Zhang, Dianke Chen, Huanliang Liu, Yisheng Wei, Jiachun Lu, Junsheng Peng, Jianping Wang.   

Abstract

Mitogen/extracellular signal-regulated kinase kinase-5 (MEK5), which belongs to a network of mitogen-activated protein kinase pathways, play a pivotal role in carcinogenesis. The purpose of this study was to investigate whether variants in the MEK5 gene promoter were involved in susceptivity of individuals to sporadic colorectal cancer (CRC). In the present hospital-based case-control study of 737 patients with sporadic CRC and 703 healthy control subjects in a southern Chinese population, the two polymorphisms of MEK5 promoter (i.e., rs7172582C>T and rs3743354T>C) were genotyped by TaqMan assay. There were significant differences between cases and controls in the genotype and allele distribution of the MEK5 gene rs3743354T>C polymorphism. The rs3743354 CC genotype was associated with a significantly decreased risk of CRC when compared with the TT genotype (adjusted odds ratios [ORs]=0.43; 95% confidence interval [CI], 0.24-0.77). Compared to the T allele, a significant correlation was detected between the presence of the C allele and decreased risk of CRC (adjusted OR=0.79; 95% CI, 0.61-0.94). The decreased risk of CRC associated with rs3743354 variant genotypes (i.e., CT+CC) was found in the smoker subgroup (adjusted OR=0.63; 95% CI=0.45-0.88). Further, environmental factors, including smoking and drinking, interacted with rs3743354C variant genotypes to reduce CRC risk. Western blot analysis showed that the levels of MEK5 protein in sporadic CRC neoplastic tissues and adjacent normal colorectal epithelium tissues were lower in the carriers of rs3743354 CC genotypes than that in those with rs3743354 TT genotypes or those with rs3743354 TC genotypes. However, no significant association was found between the rs7172582C>T polymorphism and risk of CRC. These data indicate that the rs3743354 polymorphism in the MEK5 promoter may affect the risk of developing CRC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21861603      PMCID: PMC3300074          DOI: 10.1089/dna.2011.1232

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  37 in total

Review 1.  Gene-gene, gene-environment & multiple interactions in colorectal cancer.

Authors:  Farid E Ahmed
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2006-04       Impact factor: 3.781

2.  In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis.

Authors:  Li-E Wang; Ping Xiong; Sara S Strom; Leonard H Goldberg; Jeffrey E Lee; Merrick I Ross; Paul F Mansfield; Jeffrey E Gershenwald; Victor G Prieto; Janice N Cormier; Madeleine Duvic; Gary L Clayman; Randal S Weber; Scott M Lippman; Christopher I Amos; Margaret R Spitz; Qingyi Wei
Journal:  J Natl Cancer Inst       Date:  2005-12-21       Impact factor: 13.506

3.  Breast cancer risk associated with genotypic polymorphism of the mitotic checkpoint genes: a multigenic study on cancer susceptibility.

Authors:  Yen-Li Lo; Jyh-Cherng Yu; Shou-Tung Chen; Giu-Cheng Hsu; Yi-Chien Mau; Show-Lin Yang; Pei-Ei Wu; Chen-Yang Shen
Journal:  Carcinogenesis       Date:  2007-01-08       Impact factor: 4.944

4.  Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma.

Authors:  Robert A Winn; Michelle Van Scoyk; Mandy Hammond; Karen Rodriguez; Joseph T Crossno; Lynn E Heasley; Raphael A Nemenoff
Journal:  J Biol Chem       Date:  2006-07-11       Impact factor: 5.157

Review 5.  Colorectal cancer: molecules and populations.

Authors:  J D Potter
Journal:  J Natl Cancer Inst       Date:  1999-06-02       Impact factor: 13.506

6.  c-myc Promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway.

Authors:  Asish K Ghosh; Robert Steele; Ratna B Ray
Journal:  J Biol Chem       Date:  2005-02-01       Impact factor: 5.157

7.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

8.  A novel mitogen-activated protein kinase docking site in the N terminus of MEK5alpha organizes the components of the extracellular signal-regulated kinase 5 signaling pathway.

Authors:  Jan Seyfried; Xin Wang; Giorgi Kharebava; Cathy Tournier
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

9.  Cigarettes and alcohol in relation to colorectal cancer: the Singapore Chinese Health Study.

Authors:  W H Tsong; W-P Koh; J-M Yuan; R Wang; C-L Sun; M C Yu
Journal:  Br J Cancer       Date:  2007-02-20       Impact factor: 7.640

10.  Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer.

Authors:  T J Dudderidge; S R McCracken; M Loddo; T R Fanshawe; J D Kelly; D E Neal; H Y Leung; G H Williams; K Stoeber
Journal:  Br J Cancer       Date:  2007-04-03       Impact factor: 7.640

View more
  2 in total

1.  MEK5 overexpression is associated with the occurrence and development of colorectal cancer.

Authors:  Dechang Diao; Lei Wang; Jin Wan; Zhiqiang Chen; Junsheng Peng; Huanliang Liu; Xinlin Chen; Wei Wang; Liaonan Zou
Journal:  BMC Cancer       Date:  2016-05-09       Impact factor: 4.430

2.  MKK4 variants rs3826392 and rs3809728 are associated with susceptibility and clinicopathological features in colorectal cancer patients.

Authors:  Kimberly Carol Esmeralda Martínez-Casillas; Anilú Margarita Saucedo-Sariñana; Patricio Barros-Núñez; Martha Patricia Gallegos-Arreola; Tomás Daniel Pineda-Razo; María Eugenia Marín-Contreras; Silvia Esperanza Flores-Martínez; Mónica Alejandra Rosales-Reynoso
Journal:  Iran J Basic Med Sci       Date:  2021-08       Impact factor: 2.699

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.